Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma
作者： Richard Gorlick , Andrew G. Huvos , Glenn Heller , Alex Aledo , G. Peter Beardsley
DOI: 10.1200/JCO.1999.17.9.2781
关键词:
摘要: PURPOSE: In osteosarcoma, prognostic factors at diagnosis other than clinical stage have not been clearly identified. The aim of this study was to determine whether human epidermal growth factor receptor 2 (HER2)/erbB-2, p-glycoprotein, or p53 expression correlated with histologic response preoperative chemotherapy event-free survival. PATIENTS AND METHODS: We performed a retrospective immunohistochemical on material obtained from patients treated the Memorial Sloan-Kettering Cancer Center T12 protocol between 1986 and 1993. Paraffin-embedded tissue identified 53 (73% enrolled onto protocol) stained for HER2/erbB-2, p53, p-glycoprotein using standard monoclonal antibodies methods. RESULTS: At time initial biopsy, 20 (42.6%) 47 samples demonstrated high levels HER2/erbB-2 expression. Higher frequencies were observed in metastatic disease presentation relapse. Expre...
sci-hub.se 参考文章(32)
W. F. Taylor, J. C. Ivins, K. K. Unni, J. W. Beabout, H. J. Golenzer, L. E. Black, Prognostic Variables in Osteosarcoma: A Multi-Institutional Study Journal of the National Cancer Institute. ,vol. 81, pp. 21- 30 ,(1989) , 10.1093/JNCI/81.1.21
H. S. L. Chan, G. Haddad, G. DeBoer, V. Ling, T. M. Grogan, P-GLYCOPROTEIN EXPRESSION: CRITICAL DETERMINANT IN THE RESPONSE TO OSTEOSARCOMA CHEMOTHERAPY Journal of the National Cancer Institute. ,vol. 89, pp. 1706- 1715 ,(1997) , 10.1093/JNCI/89.22.1706
J Baselga, D Tripathy, J Mendelsohn, S Baughman, C C Benz, L Dantis, N T Sklarin, A D Seidman, C A Hudis, J Moore, P P Rosen, T Twaddell, I C Henderson, L Norton, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology. ,vol. 14, pp. 737- 744 ,(1996) , 10.1200/JCO.1996.14.3.737
M Posl, M Amling, H Ritzel, M Hentz, M Werner, K Grahl, K Winkler, G Delling, P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study. General and Diagnostic Pathology. ,vol. 142, pp. 317- 325 ,(1997)
M A Levesque, H Yu, G M Clark, E P Diamandis, Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. Journal of Clinical Oncology. ,vol. 16, pp. 2641- 2650 ,(1998) , 10.1200/JCO.1998.16.8.2641
Carl W. Miller, Abdulkarim Aslo, Alvina Won, Michael Tan, Beatrice Lampkin, H. Phillip Koefflar, Alterations of the p53, Rb and MDM2 genes in osteosarcoma. Journal of Cancer Research and Clinical Oncology. ,vol. 122, pp. 559- 565 ,(1996) , 10.1007/BF01213553
Franco Bertoni, Piero Picci, Sandra Sottili, Mario Campanacci, Massimo Serra, Nicola Baldini, Katia Scotlandi, Giovanni Barbanti-Bròdano, Maria Cristina Manara, Daniela Maurici, Gaetano Bacci, Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome The New England Journal of Medicine. ,vol. 333, pp. 1380- 1385 ,(1995) , 10.1056/NEJM199511233332103
P-glycoprotein and multidrug resistance. The New England Journal of Medicine. ,vol. 334, pp. 1335- ,(1996) , 10.1056/NEJM199605163342014
Murray Aitkin, J. D. Kalbfleisch, R. L. Prentice, The Statistical Analysis of Failure Time Data. Biometrics. ,vol. 37, pp. 622- ,(1981) , 10.2307/2530581
Huvos Ag, Rosen G, Marcove Rc, Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Archives of Pathology & Laboratory Medicine. ,vol. 101, pp. 14- 18 ,(1977)